Commit Biologics
Aarhus, DK · 1 known investors
Commit Biologics develops therapeutics based on its BiCE (Bispecific Complement Engaging) platform, which uses single-domain antibodies binding the complement protein C1q to activate the complement system and selectively kill tumor cells or cells implicated in autoimmune disease. The company, a spin-out from Aarhus University, targets cancer and autoimmune diseases.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Commit Biologics do?
- Commit Biologics develops therapeutics based on its BiCE (Bispecific Complement Engaging) platform, which uses single-domain antibodies binding the complement protein C1q to activate the complement system and selectively kill tumor cells or cells implicated in autoimmune disease. The company, a spin-out from Aarhus University, targets cancer and autoimmune diseases.
- Who are Commit Biologics's investors?
- Commit Biologics's investors include Korys.
- Where is Commit Biologics headquartered?
- Commit Biologics is headquartered in Aarhus, DK.